Table 5.
Clinical trials in FLT3mut AML.
| Mutation | Study regimen | Trial identifier |
|---|---|---|
| FLT3mut AML | ||
| FLT3-ITDmut | Gilteritinib + gemtuzumab ozogamicin | NCT05199051 |
| FLT3-ITDmut | Quizartinib and 7 + 3 | NCT04676243 |
| FLT3-ITDmut | Quizartinib + venetoclax | NCT03735875 |
| FLT3mut AML | Gilteritinib + azacitidine | NCT02752035 |
| FLT3mut AML | Gilteritinib + azacitidine and venetoclax | NCT04140487 |
| FLT3mut AML | Gilteritinib + decitabine, cedazuridine, and venetoclax | NCT05010122 |
| FLT3mut AML | Gilteritinib + CPX-351 | NCT05024552 |
| FLT3mut AML | Gilteritinib + atezolizumab | NCT03730012 |
| FLT3mut AML | Gilteritinib versus midostaurin | NCT03836209 |
| FLT3mut AML | Crenolanib versus midostaurin | NCT03258931 |
| FLT3mut AML | CLN-049 (FLT3-CD3 bispecific antibody) | NCT05143996 |